We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we ...

Analysts have mixed opinions on BMY, with a “Moderate Buy” consensus from 25 analysts. Seven rate it a “Strong Buy,” 17 recommend “Hold,” and one suggests “Sell.” The average price target is $59.52, ...

International Assets Investment Management LLC cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 98.4% ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

Dependable recurring dividends from quality, high-yield stocks like these five are a recipe for passive income success.

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Highlights,Bristol-Myers Squibb beats quarterly earnings estimates.,Dividend increased, maintaining strong returns.,Insider ...

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low ...